Frequently Asked Questions
The global gastric motility disorder drugs market was valued at USD XX million in 2022.8
The gastric motility disorder drugs market is expected to grow at a CAGR of 4.9% between 2023 and 2030, reaching USD XX Million in 2030.
The prokinetic agents segment is the leading category by drug type, holding over 40% share in value in 2022.
Gastroparesis governs the global demand for gastric motility disorder drugs, holding a massive market share of over 30% in 2022.
The retail and online pharmacies segment will post the highest CAGR over the projection period.
North America is fueling the rapid growth of the gastric motility disorder drugs industry, with over one-third of its share in 2022.
The top players include Abbott, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd, Cipla Inc, Gilead Sciences Inc, Biogen, Organon Group of Companies, AbbVie Inc, AstraZeneca, Salix Pharmaceuticals, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Bayer AG, and Others.
The major market drivers of the gastric motility disorder drugs industry include the increasing prevalence of gastric motility disorders, advancements in diagnostic techniques, and the potential for innovative biologic therapies.
The major market restraints of the gastric motility disorder drugs industry comprise limited treatment options and regulatory approval challenges due to the complexity of the disorders and small patient populations.
The major market opportunities in the gastric motility disorder drugs industry encompass biologic therapies and personalized medicine approaches, as well as expansion into emerging markets with changing demographics and improved healthcare infrastructure.